Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients

Phase 1 Trial Assessing PET Imaging Agent in Local and Advanced Prostate Cancers Enrolling Patients
Cancer Targeted Technology (CTT) has initiated a Phase 1 clinical trial evaluating the safety and sensitivity of its positron emission tomography (PET) imaging agent, CTT1057, in detecting prostate cancer cells in patients with both localized and metastatic disease. The trial is supported by a $2 million Small Business Innovation Research (SBIR) grant, and imaged its first patients in early November. CTT1057, which was designated an Investigational New Drug by the U.S. Food and Drug Administration in August, is a radiolabeled (fluorine-18) antibody that binds to the prostate cancer biomarker PSMA irreversibly, enhancing the imaging agent's uptake by cancer cells. Because PSMA is expressed at high levels in prostate cancer cells, and these levels further increase if a cancer metastasizes and becomes castrate-resistant, CTT1057 holds promise in detecting metastasis with better accuracy and sensitivity than current methods. “FDA clearance and start of our first clinical trial are significant milestones for CTT as we transition to a clinical phase company. CTT’s PSMA-targeted drugs are unique,” Beatrice Langton-Webster, CTT's CEO and a principal investigator on the National Institutes of Heath's SBIR, said in a press release. “Our diagnostic agent, CTT1057, will be used alone or with our companion radiotherapeutic drug, CTT1403, targeting metastatic prostate cancer, currently undergoing IND-enabling studies.” The first-in-human trial (
Subscribe or to access all post and page content.